Project Grant R41NS145857
Award Date 9/19/25
Completion Date 8/31/26
Dollars Obligated $396K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
St. Louis, MO 63110, USA
Similar Awards
- The federal Project Grant award of $2,674,385 from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) supports research to investigate the structure-function relationship of alpha-synuclein protein strains and their impact on the clinical presentation of Lewy body dementia (LBD) and multiple system atrophy (MSA). The research aims to overcome barriers in using transgenic mouse...
- This Project Grant award of $414,191 from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) will fund research by Drexel University investigating the relationship between structural variations in alpha-synuclein (α-syn) protein fibrils and the development of distinct neurodegenerative synucleinopathies such as Lewy body dementia, Parkinson's disease, and multiple system atrophy....
- This $2,192,716 federal Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) aims to understand the role of serine-129 phosphorylation in the aggregation and spreading of α-synuclein pathology associated with Parkinson's disease, dementia with Lewy bodies, and related synucleinopathies. The project leverages novel serine-129 phospho-deficient and...
- This federal Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), part of the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, aims to establish the role of alpha-synuclein-mediated membrane permeabilization in the spread of alpha-synuclein aggregates related to Parkinson's disease and related dementias. The $406,260 award to Purdue University will leverage fluorescence lifetime imaging microscopy...
- This federal Project Grant award of $1,276,662.00 from the National Institute of Neurological Disorders and Stroke (NINDS) Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) to CND Life Sciences, Inc. in Scottsdale, AZ aims to advance the development of a minimally-invasive diagnostic test to identify patients with Essential Tremor who have deposits of phosphorylated alpha-synuclein, a hallmark of Parkinson's Disease. The project also seeks to determine if...
- This National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) Project Grant award of $275,000 to Brainstorm Therapeutics, Inc. aims to develop and validate a novel Parkinson's disease drug discovery platform using patient-derived midbrain organoids. The platform will guide therapeutic candidate identification, patient selection, and trial endpoint refinement to accelerate the development of effective disease-modifying Parkinson's treatments. Key innovations...
- The National Institute of Neurological Disorders and Stroke (NINDS) awarded Synapticure Inc., a for-profit company located in Illinois, a $2,507,054 project grant under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program. The grant, with a project period from May 2025 to April 2027, aims to develop a novel 3D in vitro platform using patient-derived induced pluripotent stem cells to model different subtypes of frontotemporal dementia (FTD),...
- This $2,723,954 federal Project Grant awarded by the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) will support research at the University of Alabama at Birmingham (UAB) to investigate the effects of 14-3-3Θ protein phosphorylation on vesicular transport and alpha-synuclein aggregation, which are implicated in Parkinson's disease and dementia with Lewy bodies. The research...
- This federal Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under CFDA Program 93.853 - Extramural Research Programs in the Neurosciences and Neurological Disorders, will provide $2,280,379 to the Regents of the University of Michigan to develop novel nanobody-based agents that can target pathogenic alpha-synuclein to block its cell-to-cell transmission. The grant aims to characterize these nanobody-based agents and assess their in vitro and in...
- This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, supports research to identify changes in synaptic vesicle-binding of alpha-synuclein as an early biomarker for Parkinson's disease (PD) and Alzheimer's disease related dementias (ADRD). The $793,535 award, with a project period from December 1, 2024 to November 30, 2029, will fund studies...